CANbridge Pharma completes US$98m Series D financing round

CANbridge Pharma, a developer of specialty healthcare products designed to treat critical medical conditions, announced the completion of a US$98 million Series D financing. The round was led by General Atlantic, a leading global growth equity firm, and WuXi AppTec.

CANbridge Pharma, a developer of specialty healthcare products designed to treat critical medical conditions, announced the completion of a US$98 million Series D financing. The round was led by General Atlantic, a leading global growth equity firm, and WuXi AppTec.

Each firm also has the option to invest up to an additional $10 million, upon the satisfaction of certain conditions by CANbridge. Additional participating investors in this round include RA Capital Management, Hudson Bay Capital Management, YuanMing Prudence Fund and Tigermed.

The proceeds, the majority of which come from prominent global investors, will be used to accelerate and expand the CANbridge rare disease pipeline through internal development and external partnerships, further build CANbridge’s commercial infrastructure and capabilities and supplement operation capital.

CANbridge has a diversified array of rare disease, including Hunterase®, for which it filed a New Drug Application (NDA) in China and has plans to commercialize the drug this year. In addition, CANbridge recently entered into the commercial stage with two approved oncology products, Caphosol®, in Chinese mainland, and NERLYNX® (neratinib), in Hong Kong.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/06/canbridge-pharma-completes-us-98m-series-d-financing-round/.

Leave a Reply

Please Login to Comment